ERBB2 and metastatic neoplasm: In the work of Smith et al. [95], through genomic profiling of 733 breast cancers with HER2 amplification, enrichment of somatic changes that promote MEK/ERK signaling in metastatic tumors with reduced progression-free survival after anti-HER2 therapy was identified.